Sage Therapeutics
Days after it closed on a $42 million Series A funding round, Karuna Pharmaceuticals has named a new chief executive officer. The company appointed industry veteran and founder of Sage Therapeutics Steven Paul as its new top officer.
Over the years there have been questions surrounding the efficacy of some medications used to treat mental health issues. Last year a Harvard professor argued on CBS’ 60 Minutes that there was little difference between a psychiatric drug and a placebo.
Days after the U.S. Food and Drug Administration provided an expedited path forward for Sage Therapeutics’ depression treatment SAGE-217, the company snagged a deal worth $575 million.
Following a meeting with the U.S. Food and Drug Administration Sage Therapeutics is seeing the goal line for potential expedited approval of its major depressive disorder (MDD) and postpartum depression (PPD) treatment, SAGE-217.
There are generally two types of antidepressants on the market. They are selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). But there are still individuals who do not respond well to these drugs and the industry continues to work on developing better and alternative treatments for depression.
Approximately 25 percent of adults in the United States will deal with some form of mental illness within a given year. It’s also estimated that many of the people who experience these problems may never report it or seek help.
Sage Therapeutics has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for brexanolone (SAGE-547) to treat postpartum depression (PPD).
Martin Shkreli’s actions were brash and often bizarre, but served as a catalyst for the pharma pricing debate.
A look at three small biotechs that big drugmakers are drooling over.
JOBS
IN THE PRESS